In recent years, four more CAR-T cell therapies have been approved by the FDA.: Tecartus (Brexucabtagene, autoleucel) was approved in 2020 for r/r MCL and r/r B-cell precursor ALL; Breyanzi (Lisocabtagene, maraleucel) was approved in 2021 to treat r/r large B-cell lymphoma, all targeting CD19; Abecma (Idecabtagene vicleucel) was also approved in 2021, targeting BCMA for the treatment of r/r MM; and Carvykti (Ciltacabtagene, autoleucel) was approved in 2022, also targeting BCMA and for the same disease as above [23]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.